# A Study of STSP-0902 Ophthalmic Solution in Healthy Subjects

> **NCT06597422** · PHASE1 · COMPLETED · sponsor: **Staidson (Beijing) Biopharmaceuticals Co., Ltd** · enrollment: 82 (actual)

## Conditions studied

- Neurotrophic Keratitis

## Interventions

- **DRUG:** STSP-0902 ophthalmic solution
- **DRUG:** STSP-0902 Placebo
- **DRUG:** STSP-0902 ophthalmic solution
- **DRUG:** STSP-0902 ophthalmic solution
- **DRUG:** STSP-0902 Placebo
- **DRUG:** STSP-0902 ophthalmic solution

## Key facts

- **NCT ID:** NCT06597422
- **Lead sponsor:** Staidson (Beijing) Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-10-20
- **Primary completion:** 2025-01-23
- **Final completion:** 2025-01-23
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06597422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06597422, "A Study of STSP-0902 Ophthalmic Solution in Healthy Subjects". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06597422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*